日本丙型肝炎病毒治疗的患者与医生偏好:一项离散选择实验
日本95名患者和118名医生关于丙肝治疗偏好的离散选择实验数据,包括给药方案、安全性、费用等属性,用于分析医患偏好差异,支持消除丙肝目标。

基本信息
资源简介
日本丙型肝炎病毒治疗的患者与医生偏好:一项离散选择实验
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集,收录 2 个文件、合计 50.66 KB,主题涵盖 Patient preference、discrete choice experiment、Japanese、hepatitis C virus、shared decision-making,可用于统计建模、特征工程与队列分析,CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment》。配套论文《Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment》发表于 Journal of Medical Economics(2025),DOI:10.1080/13696998.2025.2483572。项目资助方:This study was funded by Gilead Sciences K.K. and Gilead Sciences, Inc.。源站首次发布:2025-03-24。
【数据内容】
源站原始描述:This study was performed to evaluate patients’ and physicians’ preferences regarding hepatitis C virus (HCV) treatment in Japan, particularly focusing on direct-acting antivirals. Understanding these preferences is important for maintaining adherence to treatment necessary for achieving HCV elimination. A discrete choice experiment was conducted to identify patients’ and physicians’ preferences for HCV treatment in Japan. Eligible participants completed a preference survey via an online question…
中文译文(机器翻译,仅供快速理解,请以原文为准):本研究旨在评估日本患者和医生对丙型肝炎病毒(HCV)治疗的偏好,尤其关注直接抗病毒药物。理解这些偏好对于维持实现HCV消除所需的治疗依从性很重要。 本研究采用离散选择实验,以确定日本患者和医生对HCV治疗的偏好。符合条件的参与者通过在线问卷完成偏好调查。研究确定了八个属性及其各自水平——涉及给药方案/时间安排、安全性和自付费用。主要和次要终点为相对属性重要性(RAI)和属性水平的效用值,并在患者与医生之间进行比较,以突出差异。 患者(n=95)和医生(n=118)均最关注总自付治疗费用,其次是安全风险。虽然患者和医生的治疗偏好总体相似,但患者对总自付费用的RAI高于医生(50.4%
【数据结构与技术规格】
文件数 2 个,合计 50.66 KB。ijme_a_2483572_sm3688.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document,28.05 KB。ijme_a_2483572_sm3687.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document,22.61 KB。数据集 DOI:10.6084/m9.figshare.28652649.v1。
【主题与分类】
源站学科分类:Medicine、Environmental Sciences not elsewhere classified、Ecology、Science Policy、Infectious Diseases。主题标签:Patient preference、discrete choice experiment、Japanese、hepatitis C virus、shared decision-making、I12、C25。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面:https://tandf.figshare.com/articles/dataset/Patient_and_physician_preferences_for_treatment_of_hepatitis_C_virus_infection_in_Japan_a_discrete_choice_experiment/28652649
使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。
规范引用:Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment. Taylor & Francis. Nakamoto, Daisuke; Piao, Yi; Mizutani, Hajime; LoPresti, Michael; Chikamura, Yunosuke; Makhija, Dilip; et al
【使用注意】
· 源站最后修改于 2026-01-21,引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取(Figshare)
- 源站标题:Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment
- DOI:10.6084/m9.figshare.28652649.v1
- 发布日期:2025-03-24
- 文件数:2 个
- 文件总体积:50.66 KB
- 源站页面:https://tandf.figshare.com/articles/dataset/Patient_and_physician_preferences_for_treatment_of_hepatitis_C_virus_infection_in_Japan_a_discrete_choice_experiment/28652649
命令行下载
curl -L -o "ijme_a_2483572_sm3688.docx" "https://ndownloader.figshare.com/files/53185860"
curl -L -o "ijme_a_2483572_sm3687.docx" "https://ndownloader.figshare.com/files/53185863"
文件清单
ijme_a_2483572_sm3688.docx(28.05 KB)ijme_a_2483572_sm3687.docx(22.61 KB)
文件总体积 50.66 KB(源站 API 实测)。
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
This study was performed to evaluate patients’ and physicians’ preferences regarding hepatitis C virus (HCV) treatment in Japan, particularly focusing on direct-acting antivirals. Understanding these preferences is important for maintaining adherence to treatment necessary for achieving HCV elimination.
A discrete choice experiment was conducted to identify patients’ and physicians’ preferences for HCV treatment in Japan. Eligible participants completed a preference survey via an online questionnaire. Eight attributes and their respective levels – pertaining to dosing regimen/schedule, safety, and out-of-pocket costs – were identified. The primary and secondary endpoints were the relative attribute importance (RAI) and utility value of attribute levels, which were compared between patients and physicians to highlight differences.
Both patients (n = 95) and physicians (n = 118) showed the greatest concern for total out-of-pocket treatment costs, followed by safety risks. While patients and physicians generally shared similar treatment preferences, patients placed a higher RAI on total out-of-pocket costs than did physicians (50.4% vs. 39.4%). Conversely, patients assigned lower RAI values to the risks of nasopharyngitis and pruritus (15.2% vs. 17.9% and 11.7% vs. 16.2%, respectively). The RAI for the number of tablets taken daily was higher than that for treatment duration among patients (11.6% vs. 0.2%), but nearly equal among physicians.
The study had potential non-response bias, physicians not being actual care providers for surveyed patients, a small sample size, reliance on predefined DCE attributes, and limited participant diversity from online panels.
This study highlights the importance of patient-centered care in HCV treatment and the need to raise awareness of the public subsidy for hepatitis, and to ensure an effective access scheme for the patients. Simplifying regimens like once-daily pills and minimal monitoring may enhance treatment convenience. Improved patient–physician communication supports optimized strategies, aiding Japan’s goal of HCV elimination by 2030.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.28652649.v1(source: https://tandf.figshare.com/articles/dataset/Patient_and_physician_preferences_for_treatment_of_hepatitis_C_virus_infection_in_Japan_a_discrete_choice_experiment/28652649)。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




